9vHPV Vaccine: 16 Clinical Trials, Page 1 of 2

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Condition(s):Papillomavirus Infections; Uterine Cervical Neoplasms; Vulvar Neoplasms; Vaginal Neoplasms; Adenocarcinoma in Situ; Condylomata AcuminataLast Updated:February 25, 2020Completed

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

Condition(s):Papillomavirus InfectionsLast Updated:January 13, 2021Not yet recruiting

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Condition(s):Papillomavirus InfectionsLast Updated:January 14, 2021Recruiting

Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)

Condition(s):Warts, Genital; Neoplasms, AnalLast Updated:January 14, 2021Recruiting

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

Condition(s):Genital Warts; Anal Cancer; Anal Intraepithelial NeoplasiaLast Updated:November 27, 2018Completed

Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years

Condition(s):Dengue FeverLast Updated:December 10, 2020Not yet recruiting

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Condition(s):Cervical Cancers; Vulvar Cancers; Vaginal Cancers; Genital WartsLast Updated:November 27, 2018Completed

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

Condition(s):Papilloma Viral InfectionLast Updated:November 1, 2018Completed

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Condition(s):Human PapillomavirusLast Updated:December 14, 2018Completed

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

Condition(s):Papillomavirus InfectionsLast Updated:January 11, 2021Active, not recruiting

1 2 »

Trial Bulletin .com

Clinical Trials by Category

Clinical Trials Alphabetically

About

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.